6.3 Clinical Indications for BMD Testing and the FRAX Tool

6.3 Clinical Indications for BMD Testing and the FRAX Tool

Dual-energy x-ray absorptiometry (DXA) is the gold standard for measuring bone mineral density (BMD), diagnosing osteoporosis, estimating fracture probability, and monitoring therapy. Examinations must strictly adhere to evidence-based indications established by major professional societies to optimize clinical efficacy and avoid unjustified radiation exposure.

Official Indications for BMD Testing

The Bone Health and Osteoporosis Foundation (BHOF, formerly NOF) and the International Society for Clinical Densitometry (ISCD) establish standardized indications for axial DXA scanning (lumbar spine and proximal femur):

Universal Age-Based Screening

• Women aged 65 and older, regardless of clinical risk factors.
• Men aged 70 and older, regardless of clinical risk factors.

Risk-Factor Guided Screening (Ages 50–69)

• Postmenopausal women aged 50–64 with fracture risk factors (BMI < 21 kg/m² or weight < 127 lbs [57.6 kg], parental hip fracture, or current smoking).
• Men aged 50–69 with documented clinical risk factors for fracture or secondary bone loss.

Adult Fragility Fractures

• Any adult aged 50 or older sustaining a fragility fracture (low-energy trauma equivalent to a fall from standing height or less, excluding fingers, toes, face, and cervical spine).

Secondary Bone Loss

• Adults with conditions accelerating bone demineralization: rheumatoid arthritis, primary hyperparathyroidism, celiac disease, malabsorption, hypogonadism or premature menopause (< age 45), chronic renal failure, type 1 diabetes, or prolonged immobilization.

Medication-Induced Bone Loss

• Adults receiving bone-depleting medications, predominantly systemic glucocorticoids (prednisone equivalent ≥ 5 mg/day for ≥ 3 months).
• Patients taking aromatase inhibitors, androgen deprivation therapy, or long-term anticonvulsants.

Therapeutic Monitoring

• Individuals evaluated for pharmacologic therapy, patients on active therapy to assess response (every 1 to 2 years), or patients on bisphosphonate drug holidays.

The WHO Fracture Risk Assessment Tool (FRAX)

Although bone density accounts for 60% to 70% of skeletal strength, clinical risk factors contribute substantially to absolute fracture incidence. Developed by the World Health Organization Collaborating Centre at the University of Sheffield under Professor John A. Kanis, the Fracture Risk Assessment Tool (FRAX) integrates femoral neck BMD with clinical risk factors to calculate an individual's 10-year absolute fracture probability.

FRAX is validated for treatment-naive men and postmenopausal women aged 40 to 90 years. The model generates two distinct probabilities:

• 10-Year Probability of Hip Fracture: Likelihood of sustaining a hip fracture over the next decade.
• 10-Year Probability of Major Osteoporotic Fracture (MOF): Aggregate likelihood of sustaining a fracture of the clinical spine (symptomatic vertebral), hip, forearm (distal radius), or proximal humerus.

FRAX Clinical Variable Checklist

The computer-based FRAX calculation evaluates twelve validated parameters:

1. Age: Numerical entry between 40 and 90 years.
2. Sex: Biological sex assigned at birth.
3. Weight: Patient weight in kilograms or pounds.
4. Height: Measured height in centimeters or inches (calculates BMI).
5. Previous Fracture: Adult history of low-trauma fragility fracture.
6. Parent Fractured Hip: Maternal or paternal history of hip fracture.
7. Current Tobacco Smoking: Active cigarette smoking.
8. Glucocorticoids: Oral prednisone equivalent ≥ 5 mg/day for ≥ 3 months.
9. Rheumatoid Arthritis: Confirmed diagnosis (osteoarthritis excluded).
10. Secondary Osteoporosis: Associated disorders (type 1 diabetes, osteogenesis imperfecta, hyperthyroidism, hypogonadism, liver disease).
11. Alcohol Intake: 3 or more units daily (one unit ≈ 8–10 g ethanol; standard beer/wine or single spirit).
12. Femoral Neck BMD: Optional but recommended; entered as areal BMD (g/cm²) or T-score (NHANES III female reference database).

U.S. BHOF/NOF Clinical Intervention Thresholds

In the United States, BHOF guidelines establish explicit treatment intervention thresholds for postmenopausal women and men aged 50 and older:

• Initiate therapy if the patient has a T-score ≤ -2.5 at the femoral neck, total hip, or lumbar spine.
• Initiate therapy if the patient has a history of hip or vertebral fracture (clinical or morphometric).
• Initiate therapy if the patient exhibits osteopenia (T-score between -1.0 and -2.5) at the femoral neck or lumbar spine AND meets either FRAX threshold:
  • 10-Year Hip Fracture Probability ≥ 3.0%, OR
  • 10-Year Major Osteoporotic Fracture (MOF) Probability ≥ 20.0%.

Critical Clinical Limitations of the FRAX Model

Although FRAX is widely utilized, clinicians and technologists must recognize its key algorithmic limitations:

• Unweighted Fracture Frequency: FRAX records adult fractures as a binary input (yes/no), treating a single remote wrist fracture identically to multiple recent vertebral fractures.
• Omission of Fall Frequency: Fall propensity strongly predicts fractures, yet FRAX omits fall history and neuromuscular instability.
• Lumbar Spine Discordance: FRAX evaluates BMD solely at the femoral neck, underestimating risk when lumbar spine T-scores are substantially lower.
• Dichotomous Glucocorticoid Metric: The model assumes an average daily dose, underestimating risk in patients receiving high-dose regimens (≥ 20 mg/day).
• Excluded Biomarkers: FRAX excludes biochemical turnover markers, vitamin D status, and measured rates of bone loss.